Paediatric antiretroviral use

Prezista (darunavir) has had its licence extended to include use in the treatment of HIV in antiretroviral-experienced children and adolescents over six years and weighing at least 20kg. Prezista should always be given in combination with low-dose ritonavir and other antiretrovirals.

View Prezista drug record

Further information: Janssen-Cilag

In addition, Aptivus (tipranavir) is now licensed for the treatment of HIV in highly pre-treated adolescents 12 years of age or older with virus resistant to multiple protease inhibitors. The drug should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.

View Aptivus drug record

Further information: Boehringer Ingelheim

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more